Priya Jaisinghani
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1942738547
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $177,283 of the $239,393 with a category attached, or 74.1%. 19 manufacturers reported payments, led by Lilly USA, LLC at 56.2% of the total. 2025 is the largest year on record at $172,044, more than ten times the $657 reported in 2022. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $513.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$134K
- Novo Nordisk$81K
- Novo Nordisk AS$8K
- Corcept Therapeutics$7K
- Eli Lilly$5K
- Madrigal Pharmaceuticals$867
- plus $2K from 13 others
What the payments were for
- Consulting fees$13,9436%
- Speaking & faculty fees$177,28374%
- Travel & lodging$29,48312%
- Food & beverage$18,6198%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 218 | $134,491 |
| Novo Nordisk | 177 | $81,080 |
| Novo Nordisk AS | 6 | $8,410 |
| Corcept Therapeutics | 16 | $7,467 |
| Eli Lilly | 5 | $4,753 |
| Madrigal Pharmaceuticals | 6 | $867 |
| Boehringer Ingelheim | 5 | $585 |
| Insulet Corporation | 8 | $423 |
| Xeris Pharmaceuticals, Inc. | 4 | $327 |
| Abbott | 4 | $291 |
| Novartis | 2 | $235 |
| Perspectum Diagnostics Ltd | 2 | $103 |
| Amgen | 1 | $93 |
| Viiv Healthcare Company | 3 | $80 |
| Medtronic | 4 | $80 |
| Dexcom, Inc. | 2 | $39 |
| Merck | 1 | $35 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| BETA Bionics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$239,393 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $84,910 |
| MounjaroTirzepatide | 44 | $50,183 |
| WegovySemaglutide | 11 | $25,505 |
| JardianceEmpagliflozin | 26 | $25,461 |
| JanuviaSitagliptin Phosphate | 20 | $19,312 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 33 | $2,197 |
| Levothyroxine Sodium | 49 | $456 |
| Metformin Hcl ErMetformin Hcl | 40 | $276 |
| Metformin Hcl | 16 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $81,080 | $110,41576 claims |
| Lilly USA, LLCMounjaro | $134,491 | $50,18344 claims |
| Boehringer IngelheimJardiance | $585 | $25,46126 claims |
| MerckJanuvia | $35 | $19,31220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
- Minisha SoodNew York$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.